Baxter International (BAX)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$25.83+1.02%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Warn: Primary pillar under pressure — Adjusted EPS near $1.95 in 2026: EPS $2.05 vs $1.85.
Baxter aims for adjusted EPS near $1.95 in 2026. Sales grew 3% in Q1. The company keeps paying a small dividend. It is expanding its operating system for better performance.
Baxter lost $15 million in Q1 2026. Earnings have been volatile with recent misses. Management changes may hurt execution. Growth is slow and profit margins are weak.
The price is about 33% below our fair value near $34. Analysts expect about 2% revenue growth. Our view sees risk in earnings and execution.
Breaks if: Dividend cut or suspension
Breaks if: Adjusted EPS falls below $1.85 in FY26
Breaks if: Significant management departures or failures reported
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a mixed execution quality. The current thesis state is intact, driven by recent strong financial results, but management's volatility raises concerns.
The market appears to price in a level of fragility due to weak execution quality, despite BAX being expensive compared to peers. The expectations gap suggests that the market is not fully accounting for the recent improvements in financial performance.
Fundamentals may continue to improve if management successfully executes on its priorities, particularly in raising guidance and expanding the Baxter Growth and Performance System. However, there is a moderate risk of earnings misses given the erratic nature of recent earnings surprises.
The long-term thesis hinges on management's ability to maintain or raise guidance in upcoming calls and the performance of key sector bellwethers. Additionally, broader economic conditions, such as job growth, could impact BAX's performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company reiterated its full-year 2026 financial outlook. Positive Q2 results support this outlook and raised expectations for sales and earnings. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue growth falls below 2% YoY next year
Continue to implement and expand the Baxter Growth and Performance System as the enterprise operating system for continuous improvement.
Stated as a priority in 3 of last 4 quarters. Management emphasized expansion of the Baxter Growth and Performance System (GPS) with over 230 initiatives launched in 2026-Q1. While financials show improving revenue and operating income from $2.7B and $66M in 2026-Q1 to $2.96B and $217M in 2026-Q2, the GPS priority is a recurring focus with narrow delivery so far.
“Guided by the Baxter Growth and Performance System (GPS), focused on stabilizing the business and continuous improvement.”
“Expanded Baxter Growth and Performance System (GPS) as the enterprise operating system for continuous improvement.”
“Launched more than 230 initiatives under GPS in first quarter, with additional efforts planned throughout 2026.”
Baxter is expanding its GPS as the enterprise operating system for continuous improvement.
Overall, BAX presents a complex picture with strong recent results but significant management risks and high valuation. Not investment advice.